Tirzepatide's Presence in Breastmilk: A Study in Lactating Females
A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
Background
Tirzepatide (marketed as Mounjaro and Zepbound) is a novel dual GLP-1 and GIP receptor agonist, widely used for managing type 2 diabetes and obesity. Given its increasing use among women of reproductive age, understanding its pharmacokinetics during lactation is crucial for patient safety. Currently, there is limited data on whether tirzepatide is excreted into human breastmilk and its subsequent elimination profile.
TitrateLab articles covering Tirzepatide
Written by TitrateLab, separately from the study summarized above.
